We are live on !
Find out more
Ulys LLC Portfolio holdings
AUM
$25.4M
Turnover
0%
1-Year Est. Return
201.03%
This Fund
S&P 500
This Quarter Est. Return
+3.69%
1 Year Est. Return
+201.03%
3 Year Est. Return
-31.51%
5 Year Est. Return
-50.88%
10 Year Est. Return
–
AUM
$62M
AUM Growth
+$2.2M
(+3.7%)
Cap. Flow
$0
Cap. Flow % of AUM
Cap. Flow %
0%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
1
New
–
Increased
–
Reduced
–
Closed
–
Avg Time Held
3.8
years
Top 10 Avg Time Held
3.8
years
Top 20 Avg Time Held
3.8
years
Top Buys
No buys this quarter
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Lexicon Pharmaceuticals
LXRX
$810M
| $62M | 100% |
4,321,214
| – | – |
2013 Q2
15 quarters
|
|
Similar funds
AGEC
Ulys LLC's Q1 2017 Portfolio in Review
As of Q1 2017, Ulys LLC held 1 position worth $62M, up 3.7% from $59.8M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Trading was light in Q1 2017: portfolio turnover was 0%. Ulys LLC opened no new positions and made no exits, leaving the 1-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Ulys LLC's ten largest holdings make up 100% of its $62M portfolio in Q1 2017.
- Ulys LLC opened 0 new positions and closed 0 in Q1 2017.
- Ulys LLC's portfolio value rose 3.7% quarter-over-quarter to $62M.
Based on Ulys LLC's 13F filing for Q1 2017, filed 15 May 2017.